At @ years , differences in the primary end point of cardiac death , target-vessel myocardial infarction , and target lesion revascularization continued to diverge in favor of BES-treated patients ( @ % ) compared with BMS-treated patients ( @ % ; hazard ratio = @ ; @ % confidence interval , @-@ @ ; P < @ ) with a significant risk reduction during the second year of follow-up ( hazard ratio @-@ years = @ ; @ % confidence interval , @-@ @ ; P = @ ) .